Durect corporation reports second quarter 2024 financial results and business update

-         fda granted breakthrough therapy designation for larsucosterol in alcohol-associated hepatitis -         held type b meeting with fda to discuss phase 3 clinical trial design -         seeking to initiate phase 3 trial in 2024 with topline results expected in 2h 2026 -         webcast of earnings call today, august 13th at 4:30 p.m. et cupertino, calif.
DRRX Ratings Summary
DRRX Quant Ranking